BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 21, 2012
 |  BC Week In Review  |  Company News  |  Deals

Theravance, GlaxoSmithKline deal

At Theravance's annual meeting on May 15, stockholders approved the acquisition of 10 million Theravance shares at $21.29 by partner GlaxoSmithKline, thus raising $212.9 million. The price is a 9% premium to Theravance's close of $19.50 on March 30, before the deal was announced. The...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >